Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,714
  • Shares Outstanding, K 52,579
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,730 K
  • 60-Month Beta 2.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.24
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.27
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.26 +14.29%
on 09/25/19
2.00 -28.00%
on 09/26/19
-0.36 (-20.00%)
since 09/11/19
3-Month
0.77 +87.01%
on 07/24/19
4.72 -69.49%
on 07/12/19
-3.13 (-68.49%)
since 07/11/19
52-Week
0.77 +87.01%
on 07/24/19
6.95 -79.28%
on 10/12/18
-5.10 (-77.98%)
since 10/11/18

Most Recent Stories

More News
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 1.44 (+2.86%)
Thinking about buying stock in Beyond Meat, Canopy Growth, Marinus Pharmaceuticals, Rite Aid, or 22nd Century Group?

InvestorsObserver issues critical PriceWatch Alerts for BYND, CGC, MRNS, RAD, and XXII.

XXII : 2.04 (-0.97%)
CGC : 19.27 (-0.82%)
MRNS : 1.44 (+2.86%)
RAD : 9.40 (+2.96%)
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

All patients achieved the primary endpoint

MRNS : 1.44 (+2.86%)
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

MRNS : 1.44 (+2.86%)
NIRI Philadelphia Elects New Board Members

The Philadelphia Chapter of the National Investor Relations Institute (NIRI) announced its members elected the following new Board of Directors for a twelve month term beginning in June, 2019:

TSE : 42.28 (+6.79%)
MRNS : 1.44 (+2.86%)
WTR : 45.52 (+0.11%)
RDN : 23.32 (+1.88%)
AME : 88.51 (+0.64%)
FIVE : 130.15 (+3.58%)
AMRX : 2.72 (-5.88%)
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 1.44 (+2.86%)
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

MRNS : 1.44 (+2.86%)
Marinus Pharmaceuticals: 2Q Earnings Snapshot

RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Thursday reported a loss of $12.4 million in its second quarter.

MRNS : 1.44 (+2.86%)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

Top-line Phase 2 refractory status epilepticus (RSE) data on-track for Q3 2019

MRNS : 1.44 (+2.86%)
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression

Second proof-of-concept study for IV ganaxolone with clinically meaningful activity

MRNS : 1.44 (+2.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRNS with:

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

2nd Resistance Point 1.55
1st Resistance Point 1.49
Last Price 1.44
1st Support Level 1.36
2nd Support Level 1.29

See More

52-Week High 6.95
Fibonacci 61.8% 4.59
Fibonacci 50% 3.86
Fibonacci 38.2% 3.13
Last Price 1.44
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar